Silence Therapeutics (SLN) Expected to Announce Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Silence Therapeutics to post earnings of ($0.33) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 8:00 AM ET.

Silence Therapeutics Price Performance

Shares of SLN opened at $4.86 on Thursday. The stock has a market capitalization of $229.54 million, a PE ratio of -3.60 and a beta of 1.34. The business’s fifty day moving average price is $5.52 and its 200 day moving average price is $5.76. Silence Therapeutics has a 12-month low of $1.97 and a 12-month high of $7.78.

Institutional Investors Weigh In On Silence Therapeutics

Several large investors have recently made changes to their positions in SLN. XTX Topco Ltd bought a new stake in shares of Silence Therapeutics in the 4th quarter worth $71,000. Massar Capital Management LP acquired a new position in Silence Therapeutics during the second quarter worth about $115,000. Citadel Advisors LLC bought a new stake in Silence Therapeutics in the third quarter worth about $112,000. ADAR1 Capital Management LLC lifted its holdings in Silence Therapeutics by 26.8% in the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Silence Therapeutics in the 4th quarter worth approximately $177,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on SLN shares. Wall Street Zen upgraded shares of Silence Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Silence Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $32.60.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.